• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

静脉注射白消安的最大浓度作为静脉闭塞性疾病的决定因素:293 例造血干细胞移植儿童的药代动力学-药效学分析。

Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children.

机构信息

Institute of Pediatric Hematology and Oncology, Lyon, France.

Laboratoire de Biométrie et Biologie Evolutive, UMR CNRS 5558, Université Lyon 1, Villeurbanne, France.

出版信息

Bone Marrow Transplant. 2019 Mar;54(3):448-457. doi: 10.1038/s41409-018-0281-7. Epub 2018 Aug 14.

DOI:10.1038/s41409-018-0281-7
PMID:30108322
Abstract

Veno-occlusive disease (VOD) is a severe adverse reaction to busulfan-containing regimens used in the preparation of children for hematopoietic stem cell transplantation (HSCT). We conducted a retrospective analysis of data to examine determinants of VOD in children who received IV busulfan for HSCT conditioning. Busulfan PK parameters as well as various indices (maximal concentration-Cmax, area under the concentration-time curve-AUC) were estimated using a validated Bayesian approach. The influence of available PK, demographic, and clinical variables on the incidence of VOD was evaluated by using logistic regression and classification and regression tree (CART) analyses. Among the 293 patients included, the mean age was 6.5 years and the mean actual body weight was 26.3 kg. The incidence of VOD was 25.6%. Busulfan Cmax as well as weight <9 kg or age <3 years were identified as independent predictors of VOD in logistic regression analysis. CART analysis identified busulfan Cmax over the entire regimen as the strongest predictor of VOD. This study suggests that busulfan-associated VOD is in part a concentration-dependent reaction. In addition, the youngest children showed the highest risk of VOD. These findings may have important implications for busulfan dosing and therapeutic drug monitoring practice in HSCT children.

摘要

静脉闭塞性疾病(VOD)是儿童造血干细胞移植(HSCT)预处理方案中使用含白消安药物的严重不良反应。我们对接受 IV 白消安预处理的 HSCT 患儿的数据进行了回顾性分析,以研究 VOD 的决定因素。采用验证的贝叶斯方法估计白消安 PK 参数和各种指数(最大浓度-Cmax,浓度-时间曲线下面积-AUC)。通过逻辑回归和分类回归树(CART)分析评估了可用 PK、人口统计学和临床变量对 VOD 发生率的影响。在 293 例患者中,平均年龄为 6.5 岁,平均实际体重为 26.3kg。VOD 的发生率为 25.6%。逻辑回归分析显示,白消安 Cmax 以及体重 <9kg 或年龄 <3 岁是 VOD 的独立预测因素。CART 分析确定整个方案中的白消安 Cmax 是 VOD 的最强预测因素。本研究表明,白消安相关的 VOD 在一定程度上是一种浓度依赖性反应。此外,年龄最小的儿童 VOD 风险最高。这些发现可能对 HSCT 儿童的白消安剂量和治疗药物监测实践具有重要意义。

相似文献

1
Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children.静脉注射白消安的最大浓度作为静脉闭塞性疾病的决定因素:293 例造血干细胞移植儿童的药代动力学-药效学分析。
Bone Marrow Transplant. 2019 Mar;54(3):448-457. doi: 10.1038/s41409-018-0281-7. Epub 2018 Aug 14.
2
Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation.静脉注射白消安暴露程度与接受清髓性异基因造血细胞移植的儿童和青年成人肝静脉闭塞病发展的相关性。
Transplant Cell Ther. 2022 Apr;28(4):196-202. doi: 10.1016/j.jtct.2022.01.013. Epub 2022 Jan 19.
3
Busulfan clearance does not predict the development of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation.环磷酰胺清除率不能预测造血干细胞移植患者肝静脉闭塞病的发生。
Int J Hematol. 2020 Aug;112(2):210-216. doi: 10.1007/s12185-020-02891-0. Epub 2020 May 28.
4
Cost-Effectiveness of Defibrotide in the Prophylaxis of Veno-Occlusive Disease after Pediatric Allogeneic Stem Cell Transplantation.去纤苷预防儿童异基因干细胞移植后静脉闭塞性疾病的成本效益
Biol Blood Marrow Transplant. 2017 Jul;23(7):1128-1133. doi: 10.1016/j.bbmt.2017.03.022. Epub 2017 Mar 27.
5
Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan.在使用去纤维肽预防和静脉用白消安的儿科地中海贫血 HSCT 受者中不存在 VOD。
Br J Haematol. 2009 Nov;147(4):554-60. doi: 10.1111/j.1365-2141.2009.07871.x. Epub 2009 Aug 31.
6
Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.使用定制的基于白消安的预处理方案进行先天性血红蛋白病的异基因干细胞移植:单中心经验
Biol Blood Marrow Transplant. 2016 Jun;22(6):1043-1048. doi: 10.1016/j.bbmt.2016.03.003. Epub 2016 Mar 23.
7
Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.儿童骨髓移植中白消安剂量经贝叶斯个体化调整后静脉闭塞性疾病的风险调整监测。
Pharmacoepidemiol Drug Saf. 2008 Feb;17(2):135-43. doi: 10.1002/pds.1504.
8
Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome.白消安、美法仑和噻替派预处理治疗后发生的肝静脉闭塞性疾病:发病率、危险因素及预后
Biol Blood Marrow Transplant. 1999;5(5):306-15. doi: 10.1016/s1083-8791(99)70006-6.
9
Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children: a retrospective study of the Italian Hematology-Oncology Association-Hematopoietic Stem Cell Transplantation Group.儿童自体或异基因造血干细胞移植后窦状隙阻塞综合征/静脉闭塞性疾病:意大利血液学-肿瘤学会-造血干细胞移植组的回顾性研究。
Biol Blood Marrow Transplant. 2019 Feb;25(2):313-320. doi: 10.1016/j.bbmt.2018.09.027. Epub 2018 Sep 26.
10
Efficacy and Safety of Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.去纤维肽治疗造血干细胞移植后肝静脉闭塞病的疗效和安全性:系统评价和荟萃分析。
Semin Thromb Hemost. 2019 Nov;45(8):767-777. doi: 10.1055/s-0039-1698763. Epub 2019 Oct 18.

引用本文的文献

1
Semi-mechanistic population pharmacokinetic model incorporating glutathione S-transferase activity for personalized busulfan dosing in pediatric allogeneic hematopoietic cell transplantation.纳入谷胱甘肽 S-转移酶活性的半机制群体药代动力学模型,用于儿童异基因造血细胞移植中白消安的个体化给药。
Front Pharmacol. 2025 Aug 29;16:1632588. doi: 10.3389/fphar.2025.1632588. eCollection 2025.
2
Comparison of busulfan pharmacokinetics between four-times-daily and once-daily administration in pediatric patients: a preliminary prospective observational trial.小儿患者中白消安每日四次给药与每日一次给药的药代动力学比较:一项初步前瞻性观察性试验。
Int J Hematol. 2025 Feb;121(2):244-251. doi: 10.1007/s12185-024-03891-0. Epub 2024 Dec 3.
3
How I treat sickle cell disease with gene therapy.
我如何用基因疗法治疗镰状细胞病。
Blood. 2024 Dec 26;144(26):2693-2705. doi: 10.1182/blood.2024024519.
4
Outcomes of haploidentical bone marrow transplantation in infant acute leukemia: a single center experience.单倍体相合骨髓移植治疗婴儿急性白血病的疗效:单中心经验
Bone Marrow Transplant. 2024 Jul;59(7):1028-1030. doi: 10.1038/s41409-024-02281-8. Epub 2024 Apr 9.
5
Optimal Once-Daily Busulfan Administration in Pediatric Patients: A Simulation-Based Investigation of Intravenous Infusion Times.优化儿科患者每日一次的白消安给药方案:基于模拟的静脉输注时间研究。
Drug Des Devel Ther. 2024 Mar 20;18:871-879. doi: 10.2147/DDDT.S451970. eCollection 2024.
6
Population Pharmacokinetic Modeling for Twice-Daily Intravenous Busulfan in a Large Cohort of Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation-A 10-Year Single-Center Experience.大样本儿科造血干细胞移植患者队列中每日两次静脉注射白消安的群体药代动力学建模——一项为期10年的单中心经验
Pharmaceutics. 2023 Dec 20;16(1):0. doi: 10.3390/pharmaceutics16010013.
7
Population Pharmacokinetic Model of Intravenous Busulfan in Hematopoietic Cell Transplantation: Systematic Review and Comparative Simulations.造血细胞移植中静脉用白消安的群体药代动力学模型:系统评价和比较模拟。
Clin Pharmacokinet. 2023 Jul;62(7):955-968. doi: 10.1007/s40262-023-01275-x. Epub 2023 Jul 6.
8
The first successful bone marrow transplantation in Vietnam for a young Vietnamese boy with chronic granulomatous disease: a case report.越南首例慢性肉芽肿病患儿成功进行骨髓移植:病例报告
Front Immunol. 2023 Apr 20;14:1134852. doi: 10.3389/fimmu.2023.1134852. eCollection 2023.
9
Impact of valproic acid on busulfan pharmacokinetics: In vitro assessment of potential drug-drug interaction.丙戊酸对白消安药代动力学的影响:药物相互作用的体外评估。
PLoS One. 2023 Jan 25;18(1):e0280574. doi: 10.1371/journal.pone.0280574. eCollection 2023.
10
Implementation and Cross-Validation of a Pharmacokinetic Model for Precision Dosing of Busulfan in Hematopoietic Stem Cell Transplanted Children.用于造血干细胞移植儿童中白消安精准给药的药代动力学模型的实施与交叉验证
Pharmaceutics. 2022 Oct 1;14(10):2107. doi: 10.3390/pharmaceutics14102107.